Dr. Thomas Freier

Dr. Freier is responsible for research and development at BC3 Technologies. He has previously worked at the Center of Excellence for Biomaterials in Rostock/Germany as group leader for polymer chemistry as well as tissue engineering. Subsequently, at the University of Toronto, he focused his research on the repair of injured peripheral nerves. He was Director of R&D at Matregen, a Toronto-based start-up focused on drug delivery devices. In 2006, he co-founded Medovent; a medical device company focused on applications in urology and surgery, and has acted as CEO until 2016. From 2010 to 2013, he was also CEO of Medoderm, an affiliate of Medovent with a focus on medical devices for wound treatment. In 2017, he joined Dr. Montenegro in the management of Swiss medtech start-up Monarch Bioimplants. Dr. Freier has participated in research resulting in over 20 peer-reviewed papers published in scientific journals and has contributed to five books. He holds several international patents related to biomaterials for biomedical devices. Dr. Freier earned his PhD in chemistry at the Department of Chemistry and the Institute for Organic Catalysis Research at the University of Rostock.